

Janssen Pharmaceutical Companies of Johnson & Johnson

Devin Swanson
Principal Scientist, External Innovation
AUTM, Connect and Collaborate
October 28th, 2021

Small molecule bound Cryo-EM (electron microscope) structure to design drugs for anti-inflammatory disorders

*Credit: Discovery Sciences DTMP
Structural & Protein Sciences team*

Johnson & Johnson by the numbers

~134,500

Employees Worldwide

60

Countries where J&J has a physical presence



3 Business Segments

1. Consumer


The world's 6th largest consumer health company



2. Pharmaceuticals


The world's 4th largest pharmaceutical company

- Research & Development
- Supply Chain
- Regional Commercial Units




3. Medical Devices

The world's most comprehensive medical devices business



Janssen, R&D Global Sites



Core Discovery campuses in North America (Spring House, PA and La Jolla, CA) and Europe (Beerse, BE and Leiden, NL) exemplify our investments in world-class laboratories. South San Francisco, CA and Boston, MA sites demonstrate our commitment to also being integrated into centers of intense innovation.

11,500+
 scientists, researchers & contributors

~30
 countries with Clinical Operations

\$9.6 billion*
 invested in global pharmaceutical research & development in 2020

Discovery Sciences (DS)



* Figure according to Janssen internal financial accounting \$9.6 billion as listed in 2020 Janssen U.S. Transparency Report page 2; Johnson & Johnson 10-K, February 22, 2021, page 27

Our focus areas

End-to-end strategy focused on six therapeutic areas



**Cardiovascular
& Metabolism**



Immunology



**Infectious Diseases
& Vaccines**



Neuroscience




Oncology



**Pulmonary
Hypertension**

We are a participant, partner and accelerator in the vibrant scientific ecosystem



140+
Active collaborations spanning discovery and development, including important new assets and platforms, such as CAR-T for cancer, gene therapy for retinal disease and RNAi for Hep B, along with partnerships to drive data science into all aspects of discovering and developing transformational medicines.

External reach with a global network


Global outreach:
4 Innovation Centers,
13 JLABS,
2 JPODs

640+
companies in JJI/JLABS incubator community, including alumni and active residents


40+
investments by J&J Development Corporation in 2019

Our Modalities


Peptides



DELs



TPD



RNA-based modalities



Liver Target **Beyond the Liver**

LIVER CNS EYE KIDNEY

from treating rare diseases to common diseases

Advantages of RNA-based Medicines:

- Validated platform with commercial success
- A single platform for multiple disease indications
- Target previously undruggable targets
- Flexible and robust design for a rapidly expanding premier pipeline
- Can be used in combination therapies